Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
about
KASL clinical practice guidelines: management of chronic hepatitis BEvaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingHepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinomaSorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinomaKASL Clinical Practice Guidelines: Management of chronic hepatitis B.Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma.Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.Radiotherapeutic strategies in the management of hepatocellular carcinoma.Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.Liver Cancer Working Group report.Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study.Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma
P2860
Q26752475-BB2778AB-3DCB-4A4D-B9E0-0EC95B67D014Q26783895-0EA4901F-51F3-42C5-88BF-020C2C16E9F5Q27026753-8E44E937-EDD3-4D6A-8D24-C8533D9715F9Q28392783-C4B7ADF5-81A0-4DF1-9F54-95A10EE378EBQ28394414-00DC4F0A-5BF7-4591-8EC3-FBA165D0DCF0Q34241371-CEF29167-1A6F-4C79-8EBA-0E731D39E51EQ35963024-207CE06B-3127-4ACF-942D-BB9A40CF4C2DQ36153966-A4836908-DF58-4EBC-866E-8F21D543A3CAQ36224737-54B2675B-27F4-4377-A1C7-336C5FD2468EQ36500323-111633FF-776D-41FE-8B67-FCBB5AFD52C3Q37031750-C442C5D5-8F08-4316-B218-FA46A129F1DFQ37088265-EED92981-A55C-4726-855F-4F65A1CF19DDQ37914633-5399BD5E-587A-43EB-B30C-2DD2C7949275Q37972813-CBFA7BE2-EA72-4159-802A-26415BB6D11CQ39051743-08D6B9FC-0ECE-4C92-8295-47A718A0A0DFQ42166499-817050D5-6698-4F0B-8EF7-1221D373DD5CQ42249970-14F06B54-6B57-45FF-AEB6-64DA81CA9191Q42876514-0785914E-0211-4DE1-A0E0-15A06E95439FQ43010565-B8F85638-BEF2-422D-A39F-2DEDCA0026CAQ44025718-19B14091-4BB0-4454-BEF7-7902D5EF9189Q45766668-8591D5FD-75C1-47E0-B627-CF2C5ADA5F1CQ47174386-F9E6940D-F11F-4665-BAE5-32E82760F9B8Q53324924-73D712CA-F4DA-4B92-BEB7-27E3AF696739Q53528140-8F4997E4-FEEB-4BEB-8A6E-853155AC02E1Q55656869-60C9C0DC-5623-4D15-9C52-1C2D43DF3EDAQ57222484-93EB0190-D5A6-4F86-A8FE-48E8D5C32670
P2860
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Practical efficacy of sorafeni ...... epatitis B virus-endemic area.
@en
Practical efficacy of sorafeni ...... epatitis B virus-endemic area.
@nl
type
label
Practical efficacy of sorafeni ...... epatitis B virus-endemic area.
@en
Practical efficacy of sorafeni ...... epatitis B virus-endemic area.
@nl
prefLabel
Practical efficacy of sorafeni ...... epatitis B virus-endemic area.
@en
Practical efficacy of sorafeni ...... epatitis B virus-endemic area.
@nl
P2093
P1476
Practical efficacy of sorafeni ...... epatitis B virus-endemic area.
@en
P2093
Bum Joon Park
Chang-Min Kim
Joong-Won Park
Ju Hyun Shim
P2888
P304
P356
10.1007/S00432-008-0496-X
P50
P577
2008-10-10T00:00:00Z
P6179
1003539455